Stanford
http://www.stanfordgroup.com/#Stanford provides institutional investment services and private wealth management services. The firm also offers equity research to its clients in the consumer, media, energy, financial, healthcare, technology and water/environment sectors.
View Older Stories View More Recent Stories
-
The first Virtual Microscope of the human brain, developed by Darmiyan, accurately measures Alzheimer's-related abnormalities
-
Stanford Center for Health Education Launches Online Program in Artificial Intelligence in Healthcare to Improve Patient Outcomes
-
Trevena (TRVN) Confirms FDA Approval of OLINVYK injection
-
Aditx Therapeutics Inc. (ADTX) Introduces AditxtScore for COVID-19 and Announces the Completion of Validation Studies by Stanford Blood Center
-
Royalty Pharma plc (RPRX) Names Henry A. Fernandez and Ted W. Love, M.D. to Board
-
Cantel Medical (CMD) Promotes Peter Clifford to President
-
Krystal Biotech (KRYS) Begins Pivotal Phase 3 Study of Beremagene Geperpavec in Patients with Dystrophic Epidermolysis Bullosa
-
Exelon Corp. (EXC) Names Marjorie Rodgers Cheshire to Board
-
Stanford Hospital Ranked Among Top 20 Hospitals Nationwide by U.S. News & World Report
-
Aspen Technology (AZPN) Names Amar Hanspal to Board
-
Kroger (KR) Subsidiary Home Chef Announces Collaboration with Impossible Foods
-
Stanford AI Lab Spinout, Snorkel AI Emerges From Stealth With $15M in Funding From Greylock and GV to Make AI Practical
-
Stanford Sonoma Offers Discount on Furniture and Equipment Solutions as COVID-19 Cases Ramp Up
-
Abeona Therapeutics (ABEO) Announces Two Presentations Related to Its RDEB Clinical Program at SPD
-
Abeona Therapeutics (ABEO) Resumes Enrollment in EB-101 Pivotal Phase 3 VIITAL Study in RDEB; Reports Progress in Patient Enrollment in MPS III Studies
-
Ciena (CIEN) Announces Hassan Ahmed to Board
-
ViacomCBS (VIACA) Appoints Naveen Chopra as EVP and CFO
-
Fluidigm (FLDM) Announces Multi-Site Study of COVID-19 Patients Utilizing Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay
-
Q2 Holdings (QTWO) Adds Margaret 'Peggy' Taylor to Board
-
FactSet (FDS) Names Robin Abrams as Board Chair
-
Stanford study finds that Notable’s drug sensitivity screening platform can identify potentially useful drugs for MDS patients refractory to standard therapies
-
Iteris (ITI) Names Anjali Joshi to Board
-
Stanford Sonoma Expands Offerings as Pandemic Needs Continue to Surge
-
Novavax (NVAX) Names Filip Dubovsky as CMO
-
American Public Education (APEI) Announces Granetta Blevins and Daniel Pianko to Board
-
Avangrid (AGR) Announces Dennis V. Arriola as CEO
-
BeyondSpring (BYSI) Reports Positive Topline Interim Results Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for CIN Prevention
-
Stanford Graduate School of Business Launches Stanford Rebuild, a Global Innovation Sprint to Accelerate Recovery from the COVID-19 Pandemic
-
Orthofix International (OFIX) Reports Election of Jason Hannon to Board
-
Alpine Immune Sciences (ALPN) Presents Clinical Update of Phase 1 Trial of ALPN-101 in Healthy Volunteers
-
Global Internet of People, Inc. to Co-Host Two-Day F50 Global Capital Summit Spring 2020 Featuring “Elevating HealthTech Innovation” on June 16 and June 17, 2020
-
Global Internet of People, Inc. to Co-Host Two-Day F50 Global Capital Summit Spring 2020 Featuring “Elevating HealthTech Innovation” on June 16 and June 17, 2020
-
Atossa Therapeutics (ATOS) Reports COVID-19 was 'Spreading in U.S. in Late Dec. 2019"; May Have Killed Over 980 Nationwide by Mid-Jan 2020
-
Disney (DIS) Names Carlos A. Gomez as Treasurer
-
NGM Biopharmaceuticals (NGM) Names Nolan Mangini as CFO
-
Anchiano Therapeutics Ltd. (ANCN) Announces Stan Polovets as Board Chairman
-
ATARA Biotherapeutics (ATRA) Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive MS in Late-Breaking e-Poster at EAN
-
Stanford Children's Health Trauma Expert on How to Keep Children Safe at Home during COVID-19
-
ATARA Biotherapeutics (ATRA) to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at EAN
-
Disney (DIS) Names Josh D’Amaro Chairman, Disney Parks, Experiences and Products
-
Exelixis (EXEL) Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types
-
Stanford Children's Health Resumes Care Delayed by COVID-19
-
Zoom (ZM) Adds Board Member H.R. McMaster and Head of Global Public Policy and Government Relations Jonathan Kallmer to Leadership Team
-
Akebia Therapeutics (AKBA) Phase 3 Program of Vadadustat for Treatment of Anemia Due to CKD in Adult Patients on Dialysis Achieved Endpoints
-
Knight-Hennessy Scholars announces third global cohort
-
AgEagle Aerial Systems (UAVS) Appoints New Chief Executive Officer
-
TG Therapeutics (TGTX) Reports Publication of Ublituximab Phase 2 Clinical Trial Results in Multiple Sclerosis Journal
-
Gilead Sciences (GILD) Phase 3 Trial of Remdesivir in Severe COVID-19 Patients Shows Improvement
-
BeyondSpring (BYSI) Reports Formal Change to Primary Endpoint for Study 106 Phase 3 Superiority Clinical Trial with Plinabulin Following FDA Discussions
-
Affiliated Managers Group (AMG) Adds Reuben Jeffery to Board


